522 results on '"Van Veldhuisen, Dirk J"'
Search Results
2. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction.
- Author
-
Crum, Yoran, Hoendermis, Elke S., van Veldhuisen, Dirk J., van Woerden, Gijs, Lobeek, Michelle, Dickinson, Michael G., Meems, Laura M.G., Voors, Adriaan A., Rienstra, Michiel, and Gorter, Thomas M.
- Subjects
EPICARDIAL adipose tissue ,VENTRICULAR ejection fraction ,HEART failure ,AEROBIC capacity ,BODY mass index - Abstract
Aims: Obesity and epicardial adiposity play a role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF), and both are associated with increased filling pressures and reduced exercise capacity. The haemodynamic basis for these observations remains inaccurately defined. We hypothesize that an abundance of epicardial adipose tissue (EAT) within the pericardial sac is associated with haemodynamic signs of pericardial constraint. Methods and results: HFpEF patients who underwent invasive heart catheterization with simultaneous echocardiography were included. Right atrial pressure (RAP), right ventricular end‐diastolic pressure, and pulmonary capillary wedge pressure (PCWP) were invasively measured. The presence of a square root sign on the right ventricular pressure waveform and the RAP/PCWP ratio (surrogate parameters for pericardial constraint) were investigated. EAT thickness alongside the right ventricle was measured on echocardiography. Sixty‐four patients were studied, with a mean age of 73 ± 10 years, 64% women, and a mean body mass index (BMI) of 28.6 ± 5.4 kg/m2. In total, 47 patients (73%) had a square root sign. The presence of a square root sign was associated with higher BMI (29.3 vs. 26.7 kg/m2, P = 0.02), higher EAT (4.0 vs. 3.4 mm, P = 0.03), and higher RAP (9 vs. 6 mmHg, P = 0.04). Women had more EAT than men (4.1 vs. 3.5 mm, P = 0.04), despite a comparable BMI. Women with a square root sign had significantly higher EAT (4.3 vs. 3.3 mm, P = 0.02), a higher mean RAP (9 vs. 5 mmHg, P = 0.02), and a higher RAP/PCWP ratio (0.52 vs. 0.26, P = 0.002). In men, such associations were not seen, although there was no significant interaction between men and women (P > 0.05 for all analyses). Conclusions: Obesity and epicardial adiposity are associated with haemodynamic signs of pericardial constraint in patients with HFpEF. The pathophysiological and therapeutic implications of this finding need further study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Renal function and natriuresis‐guided diuretic therapy – a pre‐specified analysis from the PUSH‐AHF trial.
- Author
-
Damman, Kevin, Beldhuis, Iris E., van der Meer, Peter, Krikken, Jan A., Coster, Jenifer E., Nieuwland, Wybe, van Veldhuisen, Dirk J., Voors, Adriaan A., and ter Maaten, Jozine M.
- Subjects
KIDNEY physiology ,DIURETICS ,GLOMERULAR filtration rate ,HEART failure patients ,EPIDERMAL growth factor receptors - Abstract
Aim: In a randomized controlled trial, we recently showed that a natriuresis‐guided diuretic approach improved natriuresis and diuresis in patients with acute heart failure (HF). In this pre‐specified analysis, we investigated the association between (worsening) renal function, outcomes and the effect of intensive natriuresis‐guided loop diuretic therapy as compared with standard of care. Methods and results: The Pragmatic Urinary Sodium‐based algoritHm in Acute Heart Failure (PUSH‐AHF) trial randomized patients to natriuresis‐guided diuretic therapy or standard of care. Serum creatinine and estimated glomerular filtration rate (eGFR) were assessed at fixed timepoints, and worsening renal function (WRF) was assessed at 72 h. The primary outcome was the interaction between randomized treatment allocation, baseline eGFR and the dual primary outcome of PUSH‐AHF: total natriuresis at 24 h and time to all‐cause mortality or HF rehospitalization at 180 days. In 309 patients, median baseline eGFR was 53 (35–73) ml/min/1.73 m2, and 58% had eGFR <60 ml/min/1.73 m2. Baseline eGFR did not significantly modify the treatment effect of natriuresis‐guided diuretic therapy on natriuresis at 24 h (p for interaction = 0.730). However, baseline eGFR significantly modified the effect on all‐cause mortality and HF rehospitalization (p for interaction = 0.017): the risk of this second primary outcome was lower in patients with lower eGFR who were randomized to the natriuresis‐guided group. In the natriuresis‐guided arm, eGFR decreased more (−11.0 vs. −6.91 ml/min/1.73 m2; p = 0.002) during the first 3 days, but this effect was attenuated at discharge (−10.3 vs. −8.69 ml/min/1.73 m2; p = 0.38). WRF was more frequently observed in patients randomized to natriuresis‐guided treatment, but was not associated with worse clinical outcomes. Conclusions: Natriuresis‐guided diuretic treatment improved diuresis and natriuresis irrespective of baseline eGFR and occurrence of WRF, was effective even in patients with low eGFR, and the observed effect on eGFR was transient and not associated with worse clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study.
- Author
-
Tubben, Alwin, Tingen, Hendrea S.A., Prakken, Niek H.J., van Empel, Vanessa P.M., Gorter, Thomas M., Meems, Laura M.G., Manintveld, Olivier C., Rienstra, Michiel, Tieleman, Robert G., Glaudemans, Andor W.J.M., van Veldhuisen, Dirk J., Slart, Riemer H.J.A., Nienhuis, Hans L.A., and van der Meer, Peter
- Subjects
HEART failure ,CARDIAC amyloidosis ,SINGLE-photon emission computed tomography ,VENTRICULAR ejection fraction ,BRAIN natriuretic factor - Abstract
Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Interatrial shunting as a treatment for heart failure: Where do we stand?
- Author
-
Gorter, Thomas M., Hoendermis, Elke S., and van Veldhuisen, Dirk J.
- Subjects
HEART failure ,TREATMENT failure ,VENTRICULAR ejection fraction ,HEART assist devices ,RIGHT heart atrium ,PULMONARY artery diseases ,HEART failure patients - Abstract
This article discusses the potential use of interatrial shunt therapy as a treatment for heart failure (HF). Interatrial shunting involves creating a pathway for blood flow from the high-pressure left atrium to the low-pressure right atrium, which can reduce left-sided filling pressures and improve symptoms and exercise capacity in HF patients. Several interatrial shunt devices have been developed and tested, with varying results. The article presents the results of a study testing the V-Wave Ventura interatrial shunt device in HF patients, which showed positive outcomes in terms of safety, shunt patency, quality of life, and functional health status. However, the study has limitations, and further research is needed to determine the ideal patient population and the long-term effects of interatrial shunting as a treatment for HF. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS‐HF trial.
- Author
-
Monzo, Luca, Girerd, Nicolas, Duarte, Kevin, Ferreira, João Pedro, McMurray, John J.V., van Veldhuisen, Dirk J., Swedberg, Karl, Pocock, Stuart J., Pitt, Bertram, and Zannad, Faiez
- Subjects
HEART failure ,HEART failure patients ,VENTRICULAR ejection fraction ,PROPORTIONAL hazards models ,SUBGROUP analysis (Experimental design) ,GLOMERULAR filtration rate - Abstract
Aim: Eplerenone reduces the risk of cardiovascular death or first hospitalization for heart failure (HF) in patients with HF and a reduced ejection fraction (HFrEF), but it is still frequently underused in routine practice. We evaluated the time course of benefits of eplerenone after its initiation in HFrEF patients from the EMPHASIS‐HF trial. Methods and results: The EMPHASIS‐HF trial was a double‐blind randomized clinical trial assessing the effect of eplerenone in patients (n = 2737, mean age 68.6 ± 7.6 years, 22.3% women) with HFrEF and mild symptoms. The time trajectories for the effect of eplerenone versus placebo on the primary composite endpoint (cardiovascular death or first hospitalization for HF) were investigated using Cox proportional hazards models with truncated data at each day post‐randomization. A significant reduction in the primary composite endpoint was observed 26 days after randomization (hazard ratio 0.58; 95% confidence interval, 0.34–1.00, p = 0.049). Eplerenone was first associated with a significant reduction in the primary endpoint in 35 days or less in most subgroups, including patients with HF history ≥18 months (day 24), estimated glomerular filtration rate <60 ml/min (day 12), ischaemic HF aetiology (day 28), age ≥65 years (day 28), narrow QRS (day 30), higher MAGGIC score (day 35), lower potassium (day 30), left ventricular ejection fraction ≥30% (day 28) or already treated with beta‐blockers (day 25). Conclusions: Eplerenone provides statistically significant and clinically meaningful benefits shortly after treatment initiation in most patients, irrespective of clinical profile. This result reinforces the need for an early initiation of eplerenone in HFrEF, as part of rapidly instituting guideline‐directed medical therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Implications of worsening renal function before hospitalization for acute heart failure.
- Author
-
Wettersten, Nicholas, Duff, Stephen, Horiuchi, Yu, van Veldhuisen, Dirk J., Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C., Cannon, Chad M., Müeller, Gerhard A., Birkhahn, Robert, Taub, Pam, Vilke, Gary M., McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, and Maisel, Alan
- Subjects
HEART failure ,KIDNEY physiology ,LIPOCALIN-2 ,DIASTOLIC blood pressure ,ACUTE kidney failure - Abstract
Aims: Kidney function changes dynamically during AHF treatment, but risk factors for and consequences of worsening renal function (WRF) at hospital admission are uncertain. We aimed to determine the significance of WRF at admission for acute heart failure (AHF). Methods and results: We evaluated a subgroup of 406 patients from The Acute Kidney Injury Neutrophil gelatinase–associated lipocalin Evaluation of Symptomatic heart failure Study (AKINESIS) who had serum creatinine measurements available within 3 months before and at the time of admission. Admission WRF was primarily defined as a 0.3 mg/dL or 50% creatinine increase from preadmission. Alternative definitions evaluated were a ≥0.5 mg/dL creatinine increase, ≥25% glomerular filtration rate decrease, and an overall change in creatinine. Predictors of admission WRF were evaluated. Outcomes evaluated were length of hospitalization, a composite of adverse in‐hospital events, and the composite of death or HF readmission at 30, 90, and 365 days. Biomarkers' prognostic ability for these outcomes were evaluated in patients with admission WRF. One‐hundred six patients (26%) had admission WRF. These patients had features of more severe AHF with lower blood pressure, higher BUN, and lower serum sodium concentrations at admission. Higher BNP (odds ratio [OR] per doubling 1.16–1.28, 95% confidence interval [CI] 1.00–1.55) and lower diastolic blood pressure (OR 0.97–0.98, 95% CI 0.96–0.99) were associated with a higher odds for the three definitions of admission WRF. The primary WRF definition was not associated with a longer hospitalization, but alternative WRF definitions were (1.3 to 1.6 days longer, 95% CI 1.0–2.2). WRF across definitions was not associated with a higher odds of adverse in‐hospital events or a higher risk of death or HF readmission. In the subset of patients with WRF, biomarkers were not prognostic for any outcome. Conclusions: Admission WRF is common in AHF patients and is associated with an increased length of hospitalization, but not adverse in‐hospital events, death, or HF readmission. Among those with admission WRF, biomarkers did not risk stratify for adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome.
- Author
-
van der Hoef, Camilla C.S., Boorsma, Eva M., Emmens, Johanna E., van Essen, Bart J., Metra, Marco, Ng, Leong L., Anker, Stefan D., Dickstein, Kenneth, Mordi, Ify R., Dihoum, Adel, Lang, Chim C., van Veldhuisen, Dirk J., Lam, Carolyn S.P., and Voors, Adriaan A.
- Subjects
HEART failure ,METABOLIC syndrome ,HEART failure patients ,FATTY acid-binding proteins ,HDL cholesterol ,INTERLEUKIN-1 receptors - Abstract
Aim: The comorbidities that collectively define metabolic syndrome are common in patients with heart failure. However, the role of metabolic syndrome in the pathophysiology of heart failure is not well understood. We therefore investigated the clinical and biomarker correlates of metabolic syndrome in patients with heart failure. Methods and results: In 1103 patients with heart failure, we compared the biomarker expression using a panel of 363 biomarkers among patients with (n = 468 [42%]) and without (n = 635 [58%]) metabolic syndrome. Subsequently, a pathway overrepresentation analysis was performed to identify key biological pathways. Findings were validated in an independent cohort of 1433 patients with heart failure of whom 615 (43%) had metabolic syndrome. Metabolic syndrome was defined as the presence of three or more of five criteria, including central obesity, elevated serum triglycerides, reduced high‐density lipoprotein cholesterol, insulin resistance and hypertension. The most significantly elevated biomarkers in patients with metabolic syndrome were leptin (log2 fold change 0.92, p = 5.85 × 10−21), fatty acid‐binding protein 4 (log2 fold change 0.61, p = 1.21 × 10−11), interleukin‐1 receptor antagonist (log2 fold change 0.47, p = 1.95 × 10−13), tumour necrosis factor receptor superfamily member 11a (log2 fold change 0.35, p = 4.16 × 10−9), and proto‐oncogene tyrosine‐protein kinase receptor Ret (log2 fold change 0.31, p = 4.87 × 10−9). Network analysis identified 10 pathways in the index cohort and 6 in the validation cohort, all related to inflammation. The primary overlapping pathway in both the index and validation cohorts was up‐regulation of the natural killer cell‐mediated cytotoxicity pathway. Conclusion: Metabolic syndrome is highly prevalent in heart failure and is associated with biomarkers and pathways relating to obesity, lipid metabolism and immune responses underlying chronic inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives.
- Author
-
van Woerden, Gijs, van Veldhuisen, Dirk J., Westenbrink, B. Daan, de Boer, Rudolf A., Rienstra, Michiel, and Gorter, Thomas M.
- Subjects
- *
ADIPOSE tissues , *ADIPOSE tissue physiology , *HEART failure , *VENTRICULAR ejection fraction , *BODY mass index - Abstract
Obesity is very common in patients with heart failure with preserved ejection fraction (HFpEF) and it has been suggested that obesity plays an important role in the pathophysiology of this disease. While body mass index defines the presence of obesity, this measure provides limited information on visceral adiposity, which is probably more relevant in the pathophysiology of HFpEF. Epicardial adipose tissue is the visceral fat situated directly adjacent to the heart and recent data demonstrate that accumulation of epicardial adipose tissue is associated with the onset, symptomatology and outcome of HFpEF. However, the mechanisms by which epicardial adipose tissue may be involved in HFpEF remain unclear. It is also questioned whether epicardial adipose tissue may be a specific target for therapy for this disease. In the present review, we describe the physiology of epicardial adipose tissue and the pathophysiological transformation of epicardial adipose tissue in response to chronic inflammatory diseases, and we postulate conceptual mechanisms on how epicardial adipose tissue may be involved in HFpEF pathophysiology. Lastly, we outline potential treatment strategies, knowledge gaps and directions for further research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence.
- Author
-
Bracun, Valentina, van Essen, Bart, Voors, Adriaan A., van Veldhuisen, Dirk J., Dickstein, Kenneth, Zannad, Faiez, Metra, Marco, Anker, Stefan, Samani, Nilesh J., Ponikowski, Piotr, Filippatos, Gerasimos, Cleland, John G.F., Lang, Chim C., Ng, Leong L., Shi, Canxia, de Wit, Sanne, Aboumsallem, Joseph Pierre, Meijers, Wouter C., Klip, IJsbrand T., and van der Meer, Peter
- Subjects
INSULIN-like growth factor-binding proteins ,HEART failure ,TYPE 2 diabetes ,HEART failure patients - Abstract
Aims: Insulin like growth factor binding protein 7 (IGFBP7) is a marker of senescence secretome and a novel biomarker in patients with heart failure (HF). We evaluated the prognostic value of IGFBP7 in patients with heart failure and examined associations to uncover potential new pathophysiological pathways related to increased plasma IGFBP7 concentrations. Methods and results: We have measured plasma IGFBP7 concentrations in 2250 subjects with new‐onset or worsening heart failure (BIOSTAT‐CHF cohort). Higher IGFBP7 plasma concentrations were found in older subjects, those with worse kidney function, history of atrial fibrillation, and diabetes mellitus type 2, and in subjects with higher number of HF hospitalizations. Higher IGFBP7 levels also correlate with the levels of several circulating biomarkers, including higher NT‐proBNP, hsTnT, and urea levels. Cox regression analyses showed that higher plasma IGFBP7 concentrations were strongly associated with increased risk of all three main endpoints (hospitalization, all‐cause mortality, and combined hospitalization and mortality) (HR 1.75, 95% CI 1.25–2.46; HR 1.71, 95% CI 1.39–2.11; and HR 1.44, 95% CI 1.23–1.70, respectively). IGFBP7 remained a significant predictor of these endpoints in patients with both reduced and preserved ejection fraction. Likelihood ratio test showed significant improvement of all three risk prediction models, after adding IGFBP7 (P < 0.001). A biomarker network analysis showed that IGFBP7 levels activate different pathways involved in the regulation of the immune system. Results were externally validated in BIOSTAT‐CHF validation cohort. Conclusions: IGFPB7 presents as an independent and robust prognostic biomarker in patients with HF, with both reduced and preserved ejection fraction. We validate the previously published data showing IGFBP7 has correlations with a number of echocardiographic markers. Lastly, IGFBP7 pathways are involved in different stages of immune system regulation, linking heart failure to senescence pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Right ventricular dysfunction in patients with new-onset heart failure: longitudinal follow-up during guideline-directed medical therapy.
- Author
-
Ansari Ramandi, Mohammad Mostafa, van Melle, Joost P., Gorter, Thomas M., Hoendermis, Elke S., van Veldhuisen, Dirk J., Nauta, Jan F., van der Wal, Martje H.L., Warink‐Riemersma, Janke, Voors, Adriaan A., Dickinson, Michael G., and Warink-Riemersma, Janke
- Subjects
HEART failure ,RIGHT ventricular dysfunction ,HEART failure patients ,VENTRICULAR ejection fraction ,ATRIAL fibrillation - Abstract
Aims: Improvement in left ventricular ejection fraction (LVEF) after up-titration of guideline-directed medical therapy (GDMT) has been well described in heart failure (HF) patients. Less is known about the prevalence and clinical course of right ventricular dysfunction (RVD) in patients with new-onset HF.Methods and Results: From 2012 to 2018, 625 patients with a recent (<3 months) diagnosis of HF were referred to a specialized nurse-led HF clinic for protocolized up-titration of GDMT. RVD, defined as tricuspid annular plane systolic excursion (TAPSE) <17 mm, was assessed at baseline and at the follow-up visit. Patients were followed for the combined endpoint of all-cause mortality and HF hospitalization for a mean of 3.3 ± 1.9 years. Of the 625 patients, 241 (38.6%) patients had RVD at baseline. Patients with RVD were older, more symptomatic, had a lower LVEF, and more often had a history of cardiothoracic surgery and atrial fibrillation. After a median follow-up of 9 months, right ventricular function normalized in 49% of the patients with baseline RVD. RVD at baseline was associated with a higher risk of the combined endpoint (hazard ratio [HR] 1.62, 95% confidence interval [CI] 1.21-2.18). Right ventricular function normalization was associated with a lower risk for the combined endpoint (HR 0.56, 95% CI 0.31-0.99), independent of baseline TAPSE, age, sex, and LVEF.Conclusion: More than one-third of patients with new-onset HF have RVD. RVD is associated with a higher risk of all-cause mortality and HF hospitalization. Recovery of RVD regularly occurs during up-titration of GDMT and is associated with improved clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
- Author
-
Inciardi, Riccardo M., Pagnesi, Matteo, Lombardi, Carlo M., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos S., Lang, Chim C., Ng, Leong L., Pellicori, Pierpaolo, Ponikowski, Piotr, Samani, Nilesh J., Zannad, Faiez, van Veldhuisen, Dirk J., Solomon, Scott D., Voors, Adriaan A., and Metra, Marco
- Subjects
HEART failure ,LEFT heart atrium ,HEART failure patients ,ACE inhibitors ,ANGIOTENSIN-receptor blockers ,ATRIAL fibrillation - Abstract
Aims: Limited data exist regarding the prognostic relevance of changes in left atrial (LA) dimensions in patients with heart failure (HF). We assessed changes in LA dimension and their relation with outcomes after optimization of guideline‐directed medical therapy (GDMT) in patients with new‐onset or worsening HF. Methods and results: Left atrial diameter was assessed at baseline and 9 months after GDMT optimization in 632 patients (mean age 65.8 ± 12.1 years, 22.3% female) enrolled in BIOSTAT‐CHF. LA adverse remodelling (LAAR) was defined as an increase in LA diameter on transthoracic echocardiography between baseline and 9 months. After the 9‐month visit, patients were followed for a median of 13 further months. LAAR was observed in 247 patients (39%). Larger baseline LA diameter (odds ratio [OR] 0.90; 95% confidence interval [CI] 0.87–0.93; p < 0.001) and up‐titration to higher doses of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARBs) (OR 0.56; 95% CI 0.34–0.92; p = 0.022) were independently associated with lower likelihood of LAAR. LAAR was associated with an increased risk of the composite of all‐cause mortality or HF hospitalization (log‐rank p = 0.007 and adjusted hazard ratio 1.73, 95% CI 1.22–2.45, p = 0.002). The association was more pronounced in patients without a history of atrial fibrillation (p for interaction = 0.009). Conclusion: Among patients enrolled in BIOSTAT‐CHF, LAAR was associated with an unfavourable outcome and was prevented by ACEi/ARB up‐titration. Changes in LA dimension may be a useful marker of response to treatment and improve risk stratification in patients with HF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Distinct pathophysiological pathways in women and men with heart failure.
- Author
-
Ravera, Alice, Santema, Bernadet T., de Boer, Rudolf A., Anker, Stefan D., Samani, Nilesh J., Lang, Chim C., Ng, Leong, Cleland, John G.F., Dickstein, Kenneth, Lam, Carolyn S.P., Van Spall, Harriette G. C., Filippatos, Gerasimos, van Veldhuisen, Dirk J., Metra, Marco, Voors, Adriaan A., and Sama, Iziah E.
- Abstract
Aims: Clinical differences between women and men have been described in heart failure (HF). However, less is known about the underlying pathophysiological mechanisms. In this study, we compared multiple circulating biomarkers to gain better insights into differential HF pathophysiology between women and men. Methods and results: In 537 women and 1485 men with HF, we compared differential expression of a panel of 363 biomarkers. Then, we performed a pathway over‐representation analysis to identify differential biological pathways in women and men. Findings were validated in an independent HF cohort (575 women, 1123 men). In both cohorts, women were older and had higher left ventricular ejection fraction (LVEF). In the index and validation cohorts respectively, we found 14/363 and 12/363 biomarkers that were relatively up‐regulated in women, while 21/363 and 14/363 were up‐regulated in men. In both cohorts, the strongest up‐regulated biomarkers in women were leptin and fatty acid binding protein‐4, compared to matrix metalloproteinase‐3 in men. Similar findings were replicated in a subset of patients from both cohorts matched by age and LVEF. Pathway over‐representation analysis revealed increased activity of pathways associated with lipid metabolism in women, and neuro‐inflammatory response in men (all p < 0.0001). Conclusion: In two independent cohorts of HF patients, biomarkers associated with lipid metabolic pathways were observed in women, while biomarkers associated with neuro‐inflammatory response were more active in men. Differences in inflammatory and metabolic pathways may contribute to sex differences in clinical phenotype observed in HF, and provide useful insights towards development of tailored HF therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction.
- Author
-
Savarese, Gianluigi, Uijl, Alicia, Ouwerkerk, Wouter, Tromp, Jasper, Anker, Stefan D., Dickstein, Kenneth, Hage, Camilla, Lam, Carolyn S.P., Lang, Chim C., Metra, Marco, Ng, Leong L., Orsini, Nicola, Samani, Nilesh J., van Veldhuisen, Dirk J., Cleland, John G.F., Voors, Adriaan A., and Lund, Lars H.
- Subjects
VENTRICULAR ejection fraction ,ALDOSTERONE antagonists ,HEART failure ,BRAIN natriuretic factor ,DISEASE risk factors ,BIOMARKERS - Abstract
Aims: No biomarker has achieved widespread acceptance as a surrogate endpoint for early‐phase heart failure (HF) trials. We assessed whether changes over time in a panel of plasma biomarkers were associated with subsequent morbidity/mortality in HF with reduced ejection fraction (HFrEF). Methods and results: In 1040 patients with HFrEF from the BIOSTAT‐CHF cohort, we investigated the associations between changes in the plasma concentrations of 30 biomarkers, before (baseline) and after (9 months) attempted optimization of guideline‐recommended therapy, on top of the BIOSTAT risk score and the subsequent risk of HF hospitalization/all‐cause mortality using Cox regression models. C‐statistics were calculated to assess discriminatory power of biomarker changes/month‐nine assessment. Changes in N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and WAP four‐disulphide core domain protein HE4 (WAP‐4C) were the only independent predictors of the outcome after adjusting for their baseline plasma concentration, 28 other biomarkers (both baseline and changes), and BIOSTAT risk score at baseline. When adjusting for month‐nine rather than baseline biomarkers concentrations, only changes in NT‐proBNP were independently associated with the outcome. The C‐statistic of the model including the BIOSTAT risk score and NT‐proBNP increased by 4% when changes were considered on top of baseline concentrations and by 1% when changes in NT‐proBNP were considered on top of its month‐nine concentrations and the BIOSTAT risk score. Conclusions: Among 30 relevant biomarkers, a change over time was significantly and independently associated with HF hospitalization/all‐cause death only for NT‐proBNP. Changes over time were modestly more prognostic than baseline or end‐values alone. Changes in biomarkers should be further explored as potential surrogate endpoints in early phase HF trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?
- Author
-
Bomer, Nils, Pavez‐Giani, Mario G., Grote Beverborg, Niels, Cleland, John G. F., van Veldhuisen, Dirk J., and van der Meer, Peter
- Subjects
HEART failure ,DEFICIENCY diseases ,HEART failure patients ,UBIQUINONES ,MITOCHONDRIA ,ADENOSINE triphosphate - Abstract
Heart failure is a devastating clinical syndrome, but current therapies are unable to abolish the disease burden. New strategies to treat or prevent heart failure are urgently needed. Over the past decades, a clear relationship has been established between poor cardiac performance and metabolic perturbations, including deficits in substrate uptake and utilization, reduction in mitochondrial oxidative phosphorylation and excessive reactive oxygen species production. Together, these perturbations result in progressive depletion of cardiac adenosine triphosphate (ATP) and cardiac energy deprivation. Increasing the delivery of energy substrates (e.g., fatty acids, glucose, ketones) to the mitochondria will be worthless if the mitochondria are unable to turn these energy substrates into fuel. Micronutrients (including coenzyme Q10, zinc, copper, selenium and iron) are required to efficiently convert macronutrients to ATP. However, up to 50% of patients with heart failure are deficient in one or more micronutrients in cross‐sectional studies. Micronutrient deficiency has a high impact on mitochondrial energy production and should be considered an additional factor in the heart failure equation, moving our view of the failing myocardium away from an "an engine out of fuel" to "a defective engine on a path to self‐destruction." This summary of evidence suggests that supplementation with micronutrients—preferably as a package rather than singly—might be a potential therapeutic strategy in the treatment of heart failure patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Clinical implications of low estimated protein intake in patients with heart failure.
- Author
-
Streng, Koen W., Hillege, Hans L., ter Maaten, Jozine M., van Veldhuisen, Dirk J., Dickstein, Kenneth, Ng, Leong L., Samani, Nilesh J., Metra, Marco, Ponikowski, Piotr, Cleland, John G., Anker, Stefan D., Romaine, Simon P.R., Damman, Kevin, van der Meer, Peter, Lang, Chim C., and Voors, Adriaan A.
- Published
- 2022
- Full Text
- View/download PDF
17. Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.
- Author
-
Nath, Mintu, Romaine, Simon P.R., Koekemoer, Andrea, Hamby, Stephen, Webb, Thomas R., Nelson, Christopher P., Castellanos‐Uribe, Marcos, Papakonstantinou, Manolo, Anker, Stefan D., Lang, Chim C., Metra, Marco, Zannad, Faiez, Filippatos, Gerasimos, van Veldhuisen, Dirk J., Cleland, John G., Ng, Leong L., May, Sean T., Marelli‐Berg, Federica, Voors, Adriaan A., and Timmons, James A.
- Abstract
Aims: Chronic heart failure (CHF) is a systemic syndrome with a poor prognosis and a need for novel therapies. We investigated whether whole blood transcriptomic profiling can provide new mechanistic insights into cardiovascular (CV) mortality in CHF. Methods and results: Transcriptome profiles were generated at baseline from 944 CHF patients from the BIOSTAT‐CHF study, of whom 626 survived and 318 died from a CV cause during a follow‐up of 21 months. Multivariable analysis, including adjustment for cell count, identified 1153 genes (6.5%) that were differentially expressed between those that survived or died and strongly related to a validated clinical risk score for adverse prognosis. The differentially expressed genes mainly belonged to five non‐redundant pathways: adaptive immune response, proteasome‐mediated ubiquitin‐dependent protein catabolic process, T‐cell co‐stimulation, positive regulation of T‐cell proliferation, and erythrocyte development. These five pathways were selectively related (RV coefficients >0.20) with seven circulating protein biomarkers of CV mortality (fibroblast growth factor 23, soluble ST2, adrenomedullin, hepcidin, pentraxin‐3, WAP 4‐disulfide core domain 2, and interleukin‐6) revealing an intricate relationship between immune and iron homeostasis. The pattern of survival‐associated gene expression matched with 29 perturbagen‐induced transcriptome signatures in the iLINCS drug‐repurposing database, identifying drugs, approved for other clinical indications, that were able to reverse in vitro the molecular changes associated with adverse prognosis in CHF. Conclusion: Systematic modelling of the whole blood protein‐coding transcriptome defined molecular pathways that provide a link between clinical risk factors and adverse CV prognosis in CHF, identifying both established and new potential therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
- Author
-
Anker, Stefan D., Ponikowski, Piotr, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Metra, Marco, Piña, Ileana L., Coats, Andrew J.S., Rosano, Giuseppe, Dorigotti, Fabio, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., and Butler, Javed
- Abstract
Aim: Improving functional capacity is a key goal in heart failure (HF). This pooled analysis of FAIR‐HF and CONFIRM‐HF assessed the likelihood of improvement or deterioration in 6‐min walk test (6MWT) among iron‐deficient patients with chronic HF with reduced ejection fraction (HFrEF) receiving ferric carboxymaltose (FCM). Methods and results: Data for 760 patients (FCM: n = 454; placebo: n = 306) were analysed. The proportions of patients receiving FCM or placebo who had ≥20, ≥30, and ≥40 m improvements or ≥10 m deterioration in 6MWT at 12 and 24 weeks were assessed. Patients receiving FCM experienced a mean (standard deviation) 31.1 (62.3) m improvement in 6MWT versus 0.1 (77.1) m improvement for placebo at week 12 (difference in mean changes 26.8 [16.6–37.0]). At week 12, the odds [95% confidence interval] of 6MWT improvements of ≥20 m (odds ratio 2.16 [1.57–2.96]; p < 0.0001), ≥30 m (2.00 [1.44–2.78]; p < 0.0001), and ≥40 m (2.29 [1.60–3.27]; p < 0.0001) were greater with FCM versus placebo, while the odds of a deterioration ≥10 m were reduced with FCM versus placebo (0.55 [0.38–0.80]; p = 0.0019). Among patients who experienced 6MWT improvements of ≥20, ≥30, or ≥40 m with FCM at week 12, more than 80% sustained this improvement at week 24. Conclusion: Ferric carboxymaltose resulted in a significantly higher likelihood of improvement and a reduced likelihood of deterioration in 6MWT versus placebo among iron‐deficient patients with HF. Of the patients experiencing clinically significant improvements at week 12, the majority sustained this improvement at week 24. These results are supportive of FCM to improve exercise capacity in HF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
- Author
-
Butler, Javed, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Dorigotti, Fabio, Metra, Marco, Piña, Ileana L., Coats, Andrew J.S., Rosano, Giuseppe, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., Anker, Stefan D., and Ponikowski, Piotr
- Abstract
Aim: Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron‐deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR‐HF and CONFIRM‐HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time. Methods and results: Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between‐group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least‐square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of ≥5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), ≥10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or ≥15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a ≥5‐, ≥10‐ or ≥15‐point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24. Conclusion: Treatment of iron‐deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual‐patient level; benefits were sustained over time in most patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients.
- Author
-
van Woerden, Gijs, van Veldhuisen, Dirk J., Gorter, Thomas M., Ophuis, Bob, Saucedo‐Orozco, Huitzilihuitl, van Empel, Vanessa P.M., Willems, Tineke P., Geelhoed, Bastiaan, Rienstra, Michiel, and Westenbrink, Berend Daan
- Subjects
ECHOCARDIOGRAPHY ,HEART failure patients ,ADIPOSE tissues - Abstract
Aims: Epicardial adipose tissue (EAT) is increasingly recognized as an important factor in the pathophysiology of heart failure (HF). Cardiac magnetic resonance (CMR) imaging is the gold‐standard imaging modality to evaluate EAT size, but in contrast to echocardiography, CMR is costly and not widely available. We investigated EAT thickness on echocardiography in relation to EAT volume on CMR, and we assessed the agreement between observers for measuring echocardiographic EAT. Methods and results: Patients with HF and left ventricular ejection fraction >40% were enrolled. All patients underwent CMR imaging and transthoracic‐echocardiography. EAT volume was quantified on CMR short‐axis cine‐stacks. Echocardiographic EAT thickness was measured on parasternal long‐axis and short‐axis views. Linear regression analyses were used to assess the association between EAT volume on CMR and EAT thickness on echocardiography. Intraclass correlation coefficient (ICC) was used to assess the interobserver agreement as well as the intraobserver agreement. EAT on CMR and echocardiography was evaluated in 117 patients (mean age 71 ± 10 years, 49% women and mean left ventricular ejection fraction 54 ± 7%). Mean EAT volume on CMR was 202 ± 64 mL and ranged from 80 to 373 mL. Mean EAT thickness on echocardiography was 3.8 ± 1.5 mm and ranged from 1.7 to 10.2 mm. EAT volume on CMR and EAT thickness on echocardiography were significantly correlated (junior‐observer: r = 0.62, P < 0.001, senior‐observer: r = 0.33, P < 0.001), and up to one‐third of the variance in EAT volume was explained by EAT thickness (R2 = 0.38, P < 0.001). The interobserver agreement between junior and senior observers for measuring echocardiographic EAT was modest [ICC, 0.65 (95% confidence interval (CI) 0.47–0.77], whereas the intraobserver agreement was good (ICC 0.98, 95% CI 0.84–0.99). Conclusions: There was a modest correlation between EAT volume on CMR and EAT thickness on echocardiography. Limited agreement between junior and senior observers for measuring echocardiographic EAT was observed. EAT thickness on echocardiography is limited in estimating EAT volume. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Trace element equilibrium in acute heart failure and the effect of empagliflozin.
- Author
-
Weening, Eerde H., Al‐Mubarak, Ali A., Damman, Kevin, Voors, Adriaan A., van Veldhuisen, Dirk J., Heerspink, Hiddo J.L., Schomburg, Lutz, van der Meer, Peter, and Bomer, Nils
- Subjects
EMPAGLIFLOZIN ,TRACE elements ,HEART failure ,SODIUM-glucose cotransporter 2 inhibitors - Published
- 2023
- Full Text
- View/download PDF
22. Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS)
- Author
-
Team Medisch, Circulatory Health, de Koning, Marie-Sophie L Y, Assa, Solmaz, Maagdenberg, Carlijn G, van Veldhuisen, Dirk J, Pasch, Andreas, van Goor, Harry, Lipsic, Erik, van der Harst, Pim, Team Medisch, Circulatory Health, de Koning, Marie-Sophie L Y, Assa, Solmaz, Maagdenberg, Carlijn G, van Veldhuisen, Dirk J, Pasch, Andreas, van Goor, Harry, Lipsic, Erik, and van der Harst, Pim
- Published
- 2020
23. Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
- Author
-
Yeoh, Su E., Dewan, Pooja, Serenelli, Matteo, Ferreira, João Pedro, Pitt, Bertram, Swedberg, Karl, van Veldhuisen, Dirk J., Zannad, Faiez, Jhund, Pardeep S., and McMurray, John J. V.
- Subjects
DRUG efficacy ,STATISTICS ,CONFIDENCE intervals ,STEROID receptors ,DISEASE relapse ,OBSTRUCTIVE lung diseases ,ALDOSTERONE antagonists ,HOSPITAL care ,CARDIAC arrest ,DESCRIPTIVE statistics ,DATA analysis ,ODDS ratio ,HEART failure ,POTASSIUM-sparing diuretics ,SECONDARY analysis ,EVALUATION - Abstract
Aims Heart failure with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) individually cause significant morbidity and mortality. Their coexistence is associated with even worse outcomes, partly due to suboptimal heart failure therapy, especially underutilisation of beta-blockers. Our aim was to investigate outcomes in HFrEF patients with and without COPD, and the effects of mineralocorticoid receptor antagonists (MRAs) on outcomes. Methods and results We studied the effect of MRA therapy in a post-hoc pooled analysis of 4397 HFrEF patients in the RALES and EMPHASIS-HF trials. The primary endpoint was the composite of heart failure hospitalisation or cardiovascular death. A total of 625 (14.2%) of the 4397 patients had COPD. Patients with COPD were older, more often male, and smokers, but less frequently treated with a beta-blocker. In patients with COPD, event rates (per 100 person-years) for the primary endpoint and for all-cause mortality were 25.2 (95% confidence interval 22.1-28.7) and 17.2 (14.9-19.9), respectively, compared with 19.9 (18.8-21.1) and 12.8 (12.0-13.7) in participants without COPD. The risks of all-cause hospitalisation and sudden death were also higher in patients with COPD. The benefit of MRA, compared with placebo, was consistent in patients with or without COPD for all outcomes, e.g. hazard ratio for the primary outcome 0.66 (0.50-0.85) for COPD and 0.65 (0.58-0.73) for no COPD (interaction p = 0.93). MRA-induced hyperkalaemia was less frequent in patients with COPD. Conclusions In RALES and EMPHASIS-HF, one-in-seven patients with HFrEF had coexisting COPD. HFrEF patients with COPD had worse outcomes than those without. The benefits of MRAs were consistent, regardless of COPD status. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.
- Author
-
Maaten, Jozine M. ter, Beldhuis, Iris E., van der Meer, Peter, Krikken, Jan A., Coster, Jenifer E., Nieuwland, Wybe, van Veldhuisen, Dirk J., Voors, Adriaan A., and Damman, Kevin
- Subjects
DIURETICS ,LENGTH of stay in hospitals ,SODIUM ,RANDOMIZED controlled trials ,HOSPITAL care ,HEART failure ,ACUTE diseases - Abstract
Aims Insufficient diuretic response frequently occurs in patients admitted for acute heart failure (HF) and is associated with worse clinical outcomes. Recent studies have shown that measuring natriuresis early after hospital admission could reliably identify patients with a poor diuretic response during hospitalization who might require enhanced diuretic treatment. This study will test the hypothesis that natriuresis-guided therapy in patients with acute HF improves natriuresis and clinical outcomes. Methods The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) is a pragmatic, single-centre, randomized, controlled, open-label study, aiming to recruit 310 acute HF patients requiring treatment with intravenous loop diuretics. Patients will be randomized to natriuresis-guided therapy or standard of care. Natriuresis will be determined at set time points after initiation of intravenous loop diuretics, and treatment will be adjusted based on the urinary sodium levels in the natriuresis-guided group using a pre-specified stepwise approach of increasing doses of loop diuretics and the initiation of combination diuretic therapy. The co-primary endpoint is 24-h urinary sodium excretion after start of loop diuretic therapy and a combined endpoint of all-cause mortality or first HF rehospitalization at 6 months. Secondary endpoints include 48- and 72-h sodium excretion, length of hospital stay, and percentage change in N-terminal pro brain natriuretic peptide at 48 and 72 h. Conclusion The PUSH-AHF study will investigate whether natriuresis-guided therapy, using a pre-specified stepwise diuretic treatment approach, improves natriuresis and clinical outcomes in patients with acute HF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.
- Author
-
Ceelen, Daan, Voors, Adriaan A., Tromp, Jasper, van Veldhuisen, Dirk J., Dickstein, Kenneth, de Boer, Rudolf A., Lang, Chim C., Anker, Stefan D., Ng, Leong L., Metra, Marco, Ponikowski, Piotr, and Figarska, Sylwia M.
- Subjects
CYTOKINES ,BIOMARKERS ,FIBROBLAST growth factors ,INTERLEUKINS ,TUMOR necrosis factors ,TREFOIL factors ,HEART failure ,GROWTH differentiation factors ,BLOOD - Abstract
Aims Elevated concentrations of growth differentiation factor 15 (GDF-15) in patients with heart failure (HF) have been consistently associated with worse clinical outcomes, but what disease mechanisms high GDF-15 concentrations represent remains unclear. Here, we aim to identify activated pathophysiological pathways related to elevated GDF-15 expression in patients with HF. Methods and results In 2279 patients with HF, we measured circulating levels of 363 biomarkers. Then, we performed a pathway over-representation analysis to identify key biological pathways between patients in the highest and lowest GDF-15 concentration quartiles. Data were validated in an independent cohort of 1705 patients with HF. In both cohorts, the strongest up-regulated biomarkers in those with high GDF-15 were fibroblast growth factor 23 (FGF-23), death receptor 5 (TRAIL-R2), WNT1-inducible signalling pathway protein 1 (WISP-1), tumour necrosis factor receptor superfamily member 11a (TNFRSF11A), leucocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), and trefoil factor 3 (TFF3). Pathway over-representation analysis revealed that high GDF-15 patients had increased activity of pathways related to inflammatory processes, notably positive regulation of chemokine production; response to interleukin-6; tumour necrosis factor and death receptor activity; and positive regulation of T-cell differentiation and inflammatory response. Furthermore, we found pathways involved in regulation of insulin-like growth factor (IGF) receptor signalling and regulatory pathways of tissue, bones, and branching structures. GDF-15 quartiles significantly predicted all-cause mortality and HF hospitalization. Conclusion Patients with HF and high plasma concentrations of GDF-15 are characterized by increased activation of inflammatory pathways and pathways related to IGF-1 regulation and bone/tissue remodelling. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial.
- Author
-
ter Maaten, Jozine M., Beldhuis, Iris E., van der Meer, Peter, Krikken, Jan A., Coster, Jenifer E., Nieuwland, Wybe, van Veldhuisen, Dirk J., Voors, Adriaan A., and Damman, Kevin
- Subjects
HEART failure ,BRAIN natriuretic factor ,DESIGN failures ,LENGTH of stay in hospitals ,TREATMENT effectiveness - Abstract
Aims: Insufficient diuretic response frequently occurs in patients admitted for acute heart failure (HF) and is associated with worse clinical outcomes. Recent studies have shown that measuring natriuresis early after hospital admission could reliably identify patients with a poor diuretic response during hospitalization who might require enhanced diuretic treatment. This study will test the hypothesis that natriuresis‐guided therapy in patients with acute HF improves natriuresis and clinical outcomes. Methods: The Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) is a pragmatic, single‐centre, randomized, controlled, open‐label study, aiming to recruit 310 acute HF patients requiring treatment with intravenous loop diuretics. Patients will be randomized to natriuresis‐guided therapy or standard of care. Natriuresis will be determined at set time points after initiation of intravenous loop diuretics, and treatment will be adjusted based on the urinary sodium levels in the natriuresis‐guided group using a pre‐specified stepwise approach of increasing doses of loop diuretics and the initiation of combination diuretic therapy. The co‐primary endpoint is 24‐h urinary sodium excretion after start of loop diuretic therapy and a combined endpoint of all‐cause mortality or first HF rehospitalization at 6 months. Secondary endpoints include 48‐ and 72‐h sodium excretion, length of hospital stay, and percentage change in N‐terminal pro brain natriuretic peptide at 48 and 72 h. Conclusion: The PUSH‐AHF study will investigate whether natriuresis‐guided therapy, using a pre‐specified stepwise diuretic treatment approach, improves natriuresis and clinical outcomes in patients with acute HF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study.
- Author
-
Alnuwaysir, Ridha I. S., Beverborg, Niels Grote, Hoes, Martijn F., Markousis-Mavrogenis, George, Gomez, Karla A., van der Wal, Haye H., Cleland, John G. F., Dickstein, Kenneth, Lang, Chim C., Ng, Leong L., Ponikowski, Piotr, Anker, Stefan D., van Veldhuisen, Dirk J., Voors, Adriaan A., and van der Meer, Peter
- Subjects
STATISTICS ,IRON deficiency ,ANEMIA ,DATA analysis ,HEART failure ,CARDIO-renal syndrome - Abstract
Aims Whereas the combination of anaemia and chronic kidney disease (CKD) has been extensively studied in patients with heart failure (HF), the contribution of iron deficiency (ID) to this dysfunctional interplay is unknown. We aimed to assess clinical associates and pathophysiological pathways related to ID in this multimorbid syndrome. Methods and results We studied 2151 patients with HF from the BIOSTAT-CHF cohort. Patients were stratified based on ID (transferrin saturation <20%), anaemia (World Health Organization definition) and/or CKD (estimated glomerular filtration rate <60 ml/min/1.73m2). Patients were mainly men (73.3%), with a median age of 70.5 (interquartile range 61.4-78.1). ID was more prevalent than CKD and anaemia (63.3%, 47.2% and 35.6% respectively), with highest prevalence in those with concomitant CKD and anaemia (77.5% vs. 59.3%; p<0.001). There was a considerable overlap in biomarkers and pathways between patients with isolated ID, anaemia or CKD, or in combination, with processes related to immunity, inflammation, cell survival and cancer amongst the common pathways. Key biomarkers shared between syndromes with ID included transferrin receptor, interleukin-6, fibroblast growth factor-23, and bone morphogenetic protein 6. Having ID, either alone or on top of anaemia and/or CKD, was associated with a lower overall summary Kansas City Cardiomyopathy Questionnaire score, an impaired 6-min walk test and increased incidence of hospitalizations and/or mortality in multivariable analyses (all p<0.05). Conclusion Iron deficiency, CKD and/or anaemia in patients with HF have great overlap in biomarker profiles, suggesting common pathways associated with these syndromes. ID either alone or on top of CKD and anaemia is associated with worse quality of life, exercise capacity and prognosis of patients with worsening HF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF.
- Author
-
Mooney, Leanne, Hawkins, Nathaniel M., Jhund, Pardeep S., Redfield, Margaret M., Vaduganathan, Muthiah, Desai, Akshay S., Rouleau, Jean L., Masatoshi Minamisawa, Shah, Amil M., Lefkowitz, Martin P., Zile, Michael R., Van Veldhuisen, Dirk J., Pfeffer, Marc A., Anand, Inder S., Maggioni, Aldo P., Senni, Michele, Claggett, Brian L., Solomon, Scott D., McMurray, John J. V., and Minamisawa, Masatoshi
- Published
- 2021
- Full Text
- View/download PDF
29. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF.
- Author
-
Pagnesi, Matteo, Adamo, Marianna, Sama, Iziah E., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos S., Lang, Chim C., Ng, Leong L., Ponikowski, Piotr, Ravera, Alice, Samani, Nilesh J., Zannad, Faiez, van Veldhuisen, Dirk J., Voors, Adriaan A., and Metra, Marco
- Subjects
BRAIN natriuretic factor ,MITRAL valve insufficiency ,HEART failure patients ,HEART failure ,VENTRICULAR ejection fraction ,CHRONIC kidney failure - Abstract
Aims: Few data regarding the prevalence and prognostic impact of mitral regurgitation (MR) in patients with worsening chronic or new‐onset acute heart failure (HF) are available. We investigated the role of MR in the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT‐CHF). Methods and results: We performed a retrospective post‐hoc analysis including patients from both the index and validation BIOSTAT‐CHF cohorts with data regarding MR status. The primary endpoint was a composite of all‐cause death or HF hospitalization. Among 4023 patients included, 1653 patients (41.1%) had moderate–severe MR. Compared to others, patients with moderate–severe MR were more likely to have atrial fibrillation and chronic kidney disease and had larger left ventricular (LV) dimensions, lower LV ejection fraction (LVEF), worse quality of life, and higher plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). A primary outcome event occurred in 697 patients with, compared to 836 patients without, moderate–severe MR [Kaplan–Meier 2‐year estimate: 42.2% vs. 35.3%; hazard ratio (HR) 1.28; 95% confidence interval (CI) 1.16–1.41; log‐rank P < 0.0001]. The association between MR and the primary endpoint remained significant after adjusting for baseline variables and the previously validated BIOSTAT‐CHF risk score (adjusted HR 1.11; 95% CI 1.00–1.23; P = 0.041). Subgroup analyses showed a numerically larger impact of MR on the primary endpoint in patients with lower LVEF, larger LV end‐diastolic diameter, and higher plasma NT‐proBNP. Conclusions: Moderate–severe MR is common in patients with worsening chronic or new‐onset acute HF and is strongly associated with outcome, independently of other features related to HF severity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients.
- Author
-
Tkaczyszyn, Michał, Comín‐Colet, Josep, Voors, Adriaan A., van Veldhuisen, Dirk J., Enjuanes, Cristina, Moliner, Pedro, Drozd, Marcin, Sierpiński, Radosław, Rozentryt, Piotr, Nowak, Jolanta, Suchocki, Tomasz, Banasiak, Waldemar, Ponikowski, Piotr, van der Meer, Peter, and Jankowska, Ewa A.
- Subjects
HEART failure patients ,IRON deficiency ,ERYTHROPOIETIN ,HEART failure ,VENTRICULAR ejection fraction - Abstract
Aims: Abnormal endogenous erythropoietin (EPO) constitutes an important cause of anaemia in chronic diseases. We analysed the relationships between iron deficiency (ID) and the adequacy of endogenous EPO in anaemic heart failure (HF) patients, and the impact of abnormal EPO on 12‐month mortality. Methods and results: We investigated 435 anaemic HF patients (age: 74 ± 10 years; males: 60%; New York Heart Association class I or II: 39%; left ventricular ejection fraction: 43 ± 17%). Patients with EPO higher than expected for a given haemoglobin were considered EPO‐resistant whereas those with EPO lower than expected ‐ EPO‐deficient. ID was defined as serum ferritin <100 µg/L or 100–299 µg/L with transferrin saturation <20%. EPO‐resistant patients (22%) had more advanced HF whereas those with EPO deficiency (57%) were more frequently females and had worse renal function. Lower serum ferritin (indicating depleted body iron stores) was related to higher EPO observed/predicted ratio when adjusted for significant clinical confounders, including C‐reactive protein. One year all‐cause mortality was 28% in patients with EPO resistance compared to 17% in patients with EPO deficiency and 10% in patients with adequate EPO (log‐rank test for the comparison EPO resistance vs. adequate EPO: P = 0.02). When adjusted for other prognosticators, there was still a trend towards increased 12‐month mortality in patients with higher EPO level. Conclusion: Anaemic HF patients with endogenous EPO deficiency vs. resistance have different clinical and laboratory characteristics. In such patients, ID contributes to EPO resistance independently of inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
- Author
-
Gehlken, Carolin, Screever, Elles M., Suthahar, Navin, Meer, Peter, Westenbrink, B. Daan, Coster, Jennifer E., Van Veldhuisen, Dirk J., Boer, Rudolf A., and Meijers, Wouter C.
- Subjects
HEART failure ,ECHOCARDIOGRAPHY ,HEART disease diagnosis - Abstract
Aims: Two key echocardiographic parameters that are currently used to diagnose heart failure (HF) with preserved ejection fraction (HFpEF) are left atrial volume index (LAVi) and left ventricular mass index (LVMi). We investigated whether patients' characteristics, biomarkers, and co‐morbidities are associated with these parameters and whether the relationships differ between patients with HFpEF or HF with reduced ejection fraction (HFrEF). Methods: We consecutively enrolled 831 outpatients with typical signs and symptoms of HF and elevated N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) levels and categorized patients based upon left ventricular ejection fraction (LVEF): LVEF < 40% (HFrEF), LVEF between 40% and 50% (HF with mid‐range ejection fraction), and LVEF ≥ 50% (HFpEF). The study includes consecutively enrolled HF patients from an HF outpatient clinic at a tertiary medical centre in the Netherlands. All patients underwent baseline characterization, laboratory measurements, and echocardiography. Results: Four hundred sixty‐nine patients had HFrEF, 189 HF with mid‐range ejection fraction, and 173 HFpEF. The patients with HFrEF were rather male [HFrEF: 323 (69%); HFpEF: 80 (46%); P < 0.001], and the age was comparable (HFrEF 67 ± 13; HFpEF 70 ± 14; P = 0.069). In HFpEF, more patients had hypertension [190 (40.5%); 114 (65.9%); P < 0.001], higher body mass indices (27 ± 8; 30 ± 7; P < 0.001), and atrial fibrillation [194 (41.4); 86 (49.7); P = 0.029]. The correlation analyses showed that in HFrEF patients, LAVi was significantly associated with age (β 0.293; P < 0.001), male gender (β 0.104; P = 0.042), body mass index (β −0160; P = 0.002), diastolic blood pressure (β −0.136; P < 0.001), New York Heart Association (β 0.174; P = 0.001), atrial fibrillation (β 0.381; P < 0.001), galectin 3 (β 0.230; P < 0.001), NT‐proBNP (β 0.183; P < 0.001), estimated glomerular filtration rate (β −0.205; P < 0.001), LVEF (β −0.173; P = 0.001), and LVMi (β 0.337; P < 0.001). In HFpEF patients, only age (β 0.326; P < 0.001), atrial fibrillation (β 0.386; P < 0.001), NT‐proBNP (β 0.176; P = 0.036), and LVMi (β 0.213; P = 0.013) were associated with LAVi. Conclusions: Although LVMi and LAVi are hallmark parameters to diagnose HFpEF, they only correlate with a few characteristics of HF and mainly with atrial fibrillation. In contrast, in HFrEF patients, LAVi relates strongly to several other HF parameters. These findings underscore the complexity in visualizing the pathophysiology of HFpEF and question the relation between cardiac structural remodeling and the impact of co‐morbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Impaired High-Density Lipoprotein Function in Patients With Heart Failure.
- Author
-
Emmens, Johanna E., Congzhuo Jia, Ng, Leong L., van Veldhuisen, Dirk J., Dickstein, Kenneth, Anker, Stefan D., Lang, Chim C., Filippatos, Gerasimos, Cleland, John G. F., Metra, Marco, Voors, Adriaan A., de Boer, Rudolf A., Tietge, Uwe J. F., and Jia, Congzhuo
- Published
- 2021
- Full Text
- View/download PDF
33. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial.
- Author
-
Ferreira, João Pedro, Claggett, Brian L., Liu, Jiankang, Desai, Akshay S., Pfeffer, Marc A., Anand, Inder S., van Veldhuisen, Dirk J., Kober, Lars, Cleland, John G.F., Rouleau, Jean L., Packer, Milton, Zile, Michael R., Shi, Victor C., Lefkowitz, Martin P., Shah, Sanjiv J., Vardeny, Orly, Zannad, Faiez, Solomon, Scott D., and McMurray, John J.V.
- Subjects
HYPOKALEMIA ,HEART failure ,POTASSIUM ,CAUSES of death ,MINERALOCORTICOID receptors ,CARDIOVASCULAR disease related mortality ,HEART failure patients - Abstract
Aims: The relationship between serum potassium concentration and outcomes in patients with heart failure and preserved ejection fraction (HFpEF) is not well‐established. The aim of this study was to explore the association between serum potassium and clinical outcomes in the PARAGON‐HF trial in which 4822 patients with HFpEF were randomised to treatment with sacubitril/valsartan or valsartan. Methods and results: The relationship between serum potassium concentrations and the primary study composite outcome of total (first and recurrent) heart failure hospitalisations and cardiovascular death was analysed. Hypo‐, normo‐, and hyperkalaemia were defined as serum potassium <4 mmol/L, 4–5 mmol/L and >5 mmol/L, respectively. Both screening and time‐updated potassium (categorical and continuous spline‐transformed) were studied. Patient mean age was 73 years and 52% were women. Patients with higher baseline potassium more often had an ischaemic aetiology and diabetes and mineralocorticoid receptor antagonist treatment. Compared with normokalaemia, both time‐updated (but not screening) hypo‐ and hyperkalaemia were associated with a higher risk of the primary outcome [adjusted hazard ratio (HR) for hypokalaemia 1.55, 95% confidence interval (CI) 1.30–1.85; P < 0.001, and for hyperkalaemia HR 1.21, 95% CI 1.02–1.44; P = 0.025]. Hypokalaemia had a stronger association with a higher risk of all‐cause, cardiovascular and non‐cardiovascular death than hyperkalaemia. The association of hypokalaemia with increased risk of all‐cause and cardiovascular death was most marked in participants with impaired kidney function (interaction P < 0.05). Serum potassium did not significantly differ between sacubitril/valsartan and valsartan throughout the follow‐up. Conclusions: Both hypo‐ and hyperkalaemia were associated with heart failure hospitalisation but only hypokalaemia was associated with mortality, especially in the context of renal impairment. Hypokalaemia was as strongly associated with death from non‐cardiovascular causes as with cardiovascular death. Collectively, these findings suggest that potassium disturbances are a more of a marker of HFpEF severity rather than a direct cause of death. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
- Author
-
Ravera, Alice, Santema, Bernadet T., Sama, Iziah E., Meyer, Sven, Lombardi, Carlo M., Carubelli, Valentina, Ferreira, João Pedro, Lang, Chim C., Dickstein, Kenneth, Anker, Stefan D., Samani, Nilesh J., Zannad, Faiez, van Veldhuisen, Dirk J., Teerlink, John R., Metra, Marco, and Voors, Adriaan A.
- Subjects
PROGNOSIS ,CARDIOMYOPATHIES ,QUESTIONNAIRES ,VISUAL analog scale ,QUALITY of life - Abstract
Aims: We sought to analyse quality of life (QoL) measures derived from two questionnaires widely used in clinical trials, the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EuroQoL 5 dimensions (EQ‐5D), and to compare their prognostic value in men and women with heart failure and reduced ejection fraction (HFrEF). Methods and results: From the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT‐CHF) we compared KCCQ and EQ‐5D at baseline and after 9 months in 1276 men and 373 women with new‐onset or worsening symptoms of HFrEF, who were sub‐optimally treated and in whom there was an anticipated up‐titration of guideline‐derived medical therapies. Women had significantly worse baseline QoL (median) as compared with men, both when assessed with KCCQ overall score (KCCQ‐OS, 44 vs. 53, P < 0.001) and EQ‐5D utility score (0.62 vs. 0.73, P < 0.001). QoL improved equally in women and men at follow‐up. All summary measures of QoL were independently associated with all‐cause mortality, with KCCQ‐OS showing the most remarkable association with mortality up to 1 year compared to the EQ‐5D scores (C‐statistic 0.650 for KCCQ‐OS vs. 0.633 and 0.599 for EQ‐5D utility score and EQ‐5D visual analogue scale, respectively). QoL was associated with all outcomes analysed, both in men and women (all P for interaction with sex >0.2). Conclusion: Amongst patients with HFrEF, women reported significantly worse QoL than men. QoL was independently associated with subsequent outcome, similarly in men and women. The KCCQ in general, and the KCCQ‐OS in particular, showed the strongest independent association with outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Relationship between body mass index, cardiovascular biomarkers and incident heart failure.
- Author
-
Suthahar, Navin, Meems, Laura M.G., Groothof, Dion, Bakker, Stephan J.L., Gansevoort, Ron T., van Veldhuisen, Dirk J., and de Boer, Rudolf A.
- Subjects
BODY mass index ,BRAIN natriuretic factor ,ALDOSTERONE antagonists ,HEART failure ,BIOMARKERS ,PLASMINOGEN activators ,C-reactive protein - Abstract
Aims: There are limited data examining whether body mass index (BMI) influences the association between cardiovascular biomarkers and incident heart failure (HF). Methods and results: Thirteen biomarkers representing key HF domains were measured: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), mid‐regional pro‐A‐type natriuretic peptide (MR‐proANP), cardiac troponin T (cTnT), C‐reactive protein, procalcitonin, galectin‐3, C‐terminal pro‐endothelin‐1 (CT‐proET‐1), mid‐regional pro‐adrenomedullin, plasminogen activator inhibitor‐1, copeptin, renin, aldosterone, and cystatin‐C. Associations of biomarkers with BMI were examined using linear regression models, and with incident HF using Cox regression models. We selected biomarkers significantly associated with incident HF, and evaluated whether BMI modified these associations. Among 8202 individuals, 41% were overweight (BMI 25–30 kg/m2), and 16% were obese (BMI ≥30 kg/m2). Mean age of the cohort was 49 years (range 28–75), and 50% were women. All biomarkers except renin were associated with BMI: inverse associations were observed with NT‐proBNP, MR‐proANP, CT‐proET‐1 and aldosterone whereas positive associations were observed with the remaining biomarkers (all P ≤ 0.001). During 11.3 ± 3.1 years of follow‐up, 357 HF events were recorded. Only NT‐proBNP, MR‐proANP and cTnT remained associated with incident HF (P < 0.001), and a significant biomarker*BMI interaction was not observed (interaction P > 0.1). Combined NT‐proBNP and cTnT measurements modestly improved performance metrics of the clinical HF model in overweight (ΔC‐statistic = 0.024; likelihood ratio χ2 = 38; P < 0.001) and obese (ΔC‐statistic = 0.020; likelihood ratio χ2 = 32; P < 0.001) individuals. Conclusions: Plasma concentrations of several cardiovascular biomarkers are influenced by obesity. Only NT‐proBNP, MR‐proANP and cTnT were associated with incident HF, and BMI did not modify these associations. A combination of NT‐proBNP and cTnT improves HF risk prediction in overweight and obese individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Dapagliflozin effect on heart failure with prevalent or new‐onset atrial fibrillation.
- Author
-
Artola Arita, Vicente, Van Veldhuisen, Dirk J., and Rienstra, Michiel
- Published
- 2022
- Full Text
- View/download PDF
37. Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
- Author
-
Arita, Vicente Artola, Van Veldhuisen, Dirk J., and Rienstra, Michiel
- Subjects
- *
ATRIAL fibrillation , *CARDIOVASCULAR diseases , *IMPLANTABLE cardioverter-defibrillators , *TREATMENT effectiveness , *ADRENERGIC beta blockers , *DAPAGLIFLOZIN , *ANGIOTENSIN receptors , *HEART failure , *ANGIOTENSIN converting enzyme - Published
- 2022
- Full Text
- View/download PDF
38. Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out...?!
- Author
-
Meems, Laura M.G., van Veldhuisen, Dirk J., and de Boer, Rudolf A.
- Subjects
- *
HEART failure , *VENTRICULAR ejection fraction , *BRAIN natriuretic factor , *OBESITY , *WEIGHT loss , *HEART - Published
- 2022
- Full Text
- View/download PDF
39. What should the C ('congestive heart failure') represent in the CHA2 DS2 -VASc score?
- Author
-
Mulder, Bart A., Veldhuisen, Dirk J., Rienstra, Michiel, and van Veldhuisen, Dirk J
- Subjects
CONGESTIVE heart failure ,CEREBRAL embolism & thrombosis ,TISSUE plasminogen activator ,HEART failure patients ,STROKE ,ATRIAL fibrillation ,ANTICOAGULANTS ,RISK assessment ,HEART failure - Published
- 2020
- Full Text
- View/download PDF
40. Selenium and outcome in heart failure.
- Author
-
Bomer, Nils, Grote Beverborg, Niels, Hoes, Martijn F., Streng, Koen W., Vermeer, Mathilde, Dokter, Martin M., IJmker, Jan, Anker, Stefan D., Cleland, John G.F., Hillege, Hans L., Lang, Chim C., Ng, Leong L., Samani, Nilesh J., Tromp, Jasper, Veldhuisen, Dirk J., Touw, Daan J., Voors, Adriaan A., Meer, Peter, van Veldhuisen, Dirk J, and van der Meer, Peter
- Subjects
INDUCTIVELY coupled plasma mass spectrometry ,REACTIVE oxygen species ,SELENIUM ,HEART failure ,INTERMITTENT claudication ,LEFT heart ventricle ,RESEARCH ,RESEARCH methodology ,MEDICAL care ,ACE inhibitors ,MEDICAL cooperation ,EVALUATION research ,CARDIOVASCULAR system ,COMPARATIVE studies ,QUALITY of life ,QUESTIONNAIRES ,RESEARCH funding ,HEART physiology ,ANGIOTENSIN receptors ,STROKE volume (Cardiac output) ,LONGITUDINAL method - Abstract
Aims: Severe deficiency of the essential trace element selenium can cause myocardial dysfunction although the mechanism at cellular level is uncertain. Whether, in clinical practice, moderate selenium deficiency is associated with worse symptoms and outcome in patients with heart failure is unknown.Methods and Results: BIOSTAT-CHF is a multinational, prospective, observational cohort study that enrolled patients with worsening heart failure. Serum concentrations of selenium were measured by inductively coupled plasma mass spectrometry. Primary endpoint was a composite of all-cause mortality and hospitalization for heart failure; secondary endpoint was all-cause mortality. To investigate potential mechanisms by which selenium deficiency might affect prognosis, human cardiomyocytes were cultured in absence of selenium, and mitochondrial function and oxidative stress were assessed. Serum selenium concentration (deficiency) was <70 μg/L in 485 (20.4%) patients, who were older, more often women, had worse New York Heart Association class, more severe signs and symptoms of heart failure and poorer exercise capacity (6-min walking test) and quality of life (Kansas City Cardiomyopathy Questionnaire). Selenium deficiency was associated with higher rates of the primary endpoint [hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.06-1.42] and all-cause mortality (HR 1.52; 95% CI 1.26-1.86). In cultured human cardiomyocytes, selenium deprivation impaired mitochondrial function and oxidative phosphorylation, and increased intracellular reactive oxygen species levels.Conclusions: Selenium deficiency in heart failure patients is independently associated with impaired exercise tolerance and a 50% higher mortality rate, and impaired mitochondrial function in vitro, in human cardiomyocytes. Clinical trials are needed to investigate the effect of selenium supplements in patients with heart failure, especially if they have low plasma concentrations of selenium. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
41. Clinical importance of urinary sodium excretion in acute heart failure.
- Author
-
Damman, Kevin, Ter Maaten, Jozine M., Coster, Jenifer E., Krikken, Jan A., Deursen, Vincent M., Krijnen, Hidde K., Hofman, Mischa, Nieuwland, Wybe, Veldhuisen, Dirk J., Voors, Adriaan A., Meer, Peter, van Deursen, Vincent M, van Veldhuisen, Dirk J, and van der Meer, Peter
- Subjects
HEART failure ,EXCRETION ,HOSPITAL admission & discharge ,PATIENT readmissions - Abstract
Aims: Urinary sodium assessment has recently been proposed as a target for loop diuretic therapy in acute heart failure (AHF). We aimed to investigate the time course, clinical correlates and prognostic importance of urinary sodium excretion in AHF.Methods and Results: In a prospective cohort of 175 consecutive patients with an admission for AHF we evaluated urinary sodium excretion 6 h after initiation of loop diuretic therapy. Clinical outcome was all-cause mortality or heart failure rehospitalization. Mean age was 71 ± 14 years, and 44% were female. Median urinary sodium excretion was 130 (67-229) mmol at 6 h, 347 (211-526) mmol at 24 h, and decreased from day 2 to day 4. Lower urinary sodium excretion was independently associated with male gender, younger age, renal dysfunction and pre-admission loop diuretic use. There was a strong association between urinary sodium excretion at 6 h and 24 h urine volume (beta = 0.702, P < 0.001). Urinary sodium excretion after 6 h was a strong predictor of all-cause mortality after a median follow-up of 257 days (hazard ratio 3.81, 95% confidence interval 1.92-7.57; P < 0.001 for the lowest vs. the highest tertile of urinary sodium excretion) independent of established risk factors and urinary volume. Urinary sodium excretion was not associated with heart failure rehospitalization.Conclusion: In a modern, unselected, contemporary AHF population, low urinary sodium excretion during the first 6 h after initiation of loop diuretic therapy is associated with lower urine output in the first day and independently associated with all-cause mortality. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
42. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
- Author
-
Rossignol, Patrick, Duarte, Kevin, Girerd, Nicolas, Karoui, Moez, McMurray, John J.V., Swedberg, Karl, Veldhuisen, Dirk J., Pocock, Stuart, Dickstein, Kenneth, Zannad, Faiez, Pitt, Bertram, and van Veldhuisen, Dirk J
- Subjects
MINERALOCORTICOID receptors ,HEART failure patients ,RENIN-angiotensin system ,GLOMERULAR filtration rate ,POTASSIUM - Abstract
Background: To assess the prognostic value of mineralocorticoid receptor antagonist (MRA) initiation and change in serum potassium (K+ ) during follow-up in patients post-acute myocardial infarction with left ventricular dysfunction or chronic heart failure (HF) and reduced ejection fraction (HFrEF).Methods and Results: Risk scores for predicting cardiovascular death (primary outcome), hospitalization for HF and all-cause death were developed. K+ and other relevant time-updated clinical and biological variables were added to conventional prognostic factors when constructing these new models. EPHESUS (n = 6632) was the derivation cohort, while EMPHASIS-HF (chronic HF, n = 2737) was used as external validation cohort. The final cardiovascular death risk score included medical history, clinical and biological parameters (e.g. K+ , below or above the normal range of 4-5 mmol/L, estimated glomerular filtration rate, and anaemia), as well as aspects of treatment (any diuretic usage, MRA use or discontinuation, and beta-blocker use). The risk score performed well in both the derivation and validation cohorts and outperformed the MAGGIC score. A web-based calculator was created to allow easy determination of the risk score (http://cic-p-nancy.fr/CardiovascularriskscoreCalculator/).Conclusion: Adding time-updated variables, including K+ and MRA treatment, improved risk prediction of cardiovascular death (on top of the MAGGIC score) in patients with HF eligible for renin-angiotensin system inhibitors and MRA therapy. This new risk score including MRA usage and K+ may be of value in helping physicians to better use MRAs, avoid unnecessary and potentially detrimental permanent discontinuations, and therefore improving cardiovascular outcomes in patients with chronic HFrEF or HF after acute myocardial infarction with left ventricular dysfunction. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
43. Right-sided cardiac disease: no longer the 'dark side of the heart'.
- Author
-
Gorter, Thomas M., Veldhuisen, Dirk J., Dickinson, Michael G., and van Veldhuisen, Dirk J
- Subjects
HEART septum ,HEART diseases ,HEART failure ,HEART ,HEART ventricle diseases ,RIGHT heart ventricle ,LONGITUDINAL method ,PROGNOSIS ,PULMONARY hypertension - Published
- 2020
- Full Text
- View/download PDF
44. Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
- Author
-
Nauta, Jan F., Hummel, Yoran M., Tromp, Jasper, Ouwerkerk, Wouter, van der Meer, Peter, Jin, Xuanyi, Lam, Carolyn S.P., Bax, Jeroen J., Metra, Marco, Samani, Nilesh J., Ponikowski, Piotr, Dickstein, Kenneth, Anker, Stefan D., Lang, Chim C., Ng, Leong L., Zannad, Faiez, Filippatos, Gerasimos S., van Veldhuisen, Dirk J., van Melle, Joost P., and Voors, Adriaan A.
- Subjects
HEART failure ,ACE inhibitors ,PLASMINOGEN activators ,ANGIOTENSIN receptors ,VENTRICULAR ejection fraction ,LEFT heart ventricle ,RESEARCH ,LEFT ventricular hypertrophy ,RESEARCH methodology ,MEDICAL care ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,CARDIOVASCULAR system ,COMPARATIVE studies ,STROKE volume (Cardiac output) ,HEART physiology - Abstract
Aims: Heart failure is traditionally classified by left ventricular ejection fraction (LVEF), rather than by left ventricular (LV) geometry, with guideline-recommended therapies in heart failure with reduced ejection fraction (HFrEF) but not heart failure with preserved ejection fraction (HFpEF). Most patients with HFrEF have eccentric LV hypertrophy, but some have concentric LV hypertrophy. We aimed to compare clinical characteristics, biomarker patterns, and response to treatment of patients with HFrEF and eccentric vs. concentric LV hypertrophy.Methods and Results: We performed a retrospective post-hoc analysis including 1015 patients with HFrEF (LVEF <40%) from the multinational observational BIOSTAT-CHF study. LV geometry was classified using two-dimensional echocardiography. Network analysis of 92 biomarkers was used to investigate pathophysiologic pathways. Concentric LV hypertrophy was present in 142 (14%) patients, who were on average older and more likely hypertensive compared to those with eccentric LV hypertrophy. Network analysis revealed that N-terminal pro-B-type natriuretic peptide was an important hub in eccentric hypertrophy, whereas in concentric hypertrophy, tumour necrosis factor receptor 1, urokinase plasminogen activator surface receptor, paraoxonase and P-selectin were central hubs. Up-titration of beta-blockers was associated with a mortality benefit in HFrEF with eccentric but not concentric LV hypertrophy (P-value for interaction ≤0.001). For angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, the hazard ratio for mortality was higher in concentric hypertrophy, but the interaction was not significant.Conclusion: Patients with HFrEF with concentric hypertrophy have a clinical and biomarker phenotype that is distinctly different from those with eccentric hypertrophy. Patients with concentric hypertrophy may not experience similar benefit from up.-titration of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers compared to patients with eccentric hypertrophy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
45. Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure.
- Author
-
Wal, Haye H., Beverborg, Niels Grote, ter Maaten, Jozine M., Vinke, Joanna S.J., Borst, Martin H., Veldhuisen, Dirk J., Voors, Adriaan A., Meer, Peter, van der Wal, Haye H, de Borst, Martin H, van Veldhuisen, Dirk J, and van der Meer, Peter
- Subjects
FIBROBLAST growth factors ,IRON deficiency ,HYPERPHOSPHATEMIA ,HEART failure ,LEFT heart ventricle ,RESEARCH ,IRON ,RESEARCH methodology ,ACE inhibitors ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,IRON deficiency anemia ,HEART physiology ,STROKE volume (Cardiac output) ,ANGIOTENSIN receptors ,DISEASE complications - Published
- 2020
- Full Text
- View/download PDF
46. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
- Author
-
Pandhi, Paloma, Maaten, Jozine M., Emmens, Johanna E., Struck, Joachim, Bergmann, Andreas, Cleland, John G., Givertz, Michael M., Metra, Marco, O'Connor, Christopher M., Teerlink, John R., Ponikowski, Piotr, Cotter, Gad, Davison, Beth, Veldhuisen, Dirk J., Voors, Adriaan A., Ter Maaten, Jozine M, and van Veldhuisen, Dirk J
- Subjects
PATIENT readmissions ,HEART failure ,HOSPITAL admission & discharge ,BRAIN natriuretic factor ,ODDS ratio ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,MEMBRANE proteins ,PEPTIDE hormones ,DISCHARGE planning - Abstract
Aims: Recently, bio-adrenomedullin (bio-ADM) was proposed as a congestion marker in heart failure (HF). In the present study, we aimed to study whether bio-ADM levels at discharge from a hospital admission for worsening HF could provide additional information on (residual) congestion status, diuretic dose titration and clinical outcomes.Methods and Results: Plasma bio-ADM was measured in 1236 acute HF patients in the PROTECT trial at day 7 or discharge. Median discharge bio-ADM was 33.7 [21.5-61.5] pg/mL. Patients with higher discharge bio-ADM levels were hospitalised longer, had higher brain natriuretic peptide levels, and poorer diuretic response (all P < 0.001). Bio-ADM was the strongest predictor of discharge residual congestion (clinical congestion score > 3) (odds ratio 4.35, 95% confidence interval 3.37-5.62; P < 0.001). Oedema at discharge was one of the strongest predictors of discharge bio-ADM (β = 0.218; P < 0.001). Higher discharge loop diuretic doses were associated with a poorer diuretic response during hospitalisation (β = 0.187; P < 0.001) and higher bio-ADM levels (β = 0.084; P = 0.020). High discharge bio-ADM levels combined with higher use of loop diuretics were independently associated with a greater risk of 60-day HF rehospitalisation (hazard ratio 4.02, 95% confidence interval 2.23-7.26; P < 0.001).Conclusion: In hospitalised HF patients, elevated pre-discharge bio-ADM levels were associated with higher discharge loop diuretic doses and reflected residual congestion. Patients with combined higher bio-ADM levels and higher loop diuretic use at discharge had an increased risk of rehospitalisation. Assessment of discharge bio-ADM levels may be a readily applicable marker to identify patients with residual congestion at higher risk of early hospital readmission. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
47. Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
- Author
-
Cao, Thong H., Jones, Donald J.L., Voors, Adriaan A., Quinn, Paulene A., Sandhu, Jatinderpal K., Chan, Daniel C.S., Parry, Helen M., Mohan, Mohapradeep, Mordi, Ify R., Sama, Iziah E., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, Hillege, Hans L., Metra, Marco, Ponikowski, Piotr, Samani, Nilesh J., Van Veldhuisen, Dirk J., and Zannad, Faiez
- Subjects
HEART failure patients ,DISEASE progression ,TANDEM mass spectrometry ,PROLINE metabolism ,PROTEIN-protein interactions ,HEART failure treatment ,LEFT heart ventricle ,BLOOD plasma ,ACE inhibitors ,MEDICAL care ,PROTEOMICS ,CARDIOVASCULAR system ,MASS spectrometry ,STROKE volume (Cardiac output) ,ANGIOTENSIN receptors ,HEART physiology - Abstract
Aims: To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with heart failure by investigation of the plasma proteome using network analysis.Methods and Results: The plasma proteome of 50 patients with heart failure who died or were rehospitalised were compared with 50 patients with heart failure, matched for age and sex, who did not have an event. Peptides were analysed on two-dimensional liquid chromatography coupled to tandem mass spectrometry (2D LC ESI-MS/MS) in high definition mode (HDMSE). We identified and quantified 3001 proteins, of which 51 were significantly up-regulated and 46 down-regulated with more than two-fold expression changes in those who experienced death or rehospitalisation. Gene ontology enrichment analysis and protein-protein interaction networks of significant differentially expressed proteins discovered the central role of metabolic processes in clinical outcomes of patients with heart failure. The findings revealed that a cluster of proteins related to glutathione metabolism, arginine and proline metabolism, and pyruvate metabolism in the pathogenesis of poor outcome in patients with heart failure who died or were rehospitalised.Conclusions: Our findings show that in patients with heart failure who died or were rehospitalised, the glutathione, arginine and proline, and pyruvate pathways were activated. These pathways might be potential targets for therapies to improve poor outcomes in patients with heart failure. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
48. Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study.
- Author
-
Ferreira, João Pedro, Ouwerkerk, Wouter, Tromp, Jasper, Ng, Leong, Dickstein, Kenneth, Anker, Stefan, Filippatos, Gerasimos, Cleland, John G., Metra, Marco, Veldhuisen, Dirk J., Voors, Adriaan A., Zannad, Faiez, and van Veldhuisen, Dirk J
- Subjects
BRAIN natriuretic factor ,OBSTRUCTIVE lung diseases ,HYPOTENSION ,PATIENT selection ,GLOMERULAR filtration rate ,TROPONIN ,RESEARCH ,RESEARCH methodology ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,PEPTIDE hormones ,HEART failure ,PEPTIDES - Abstract
Aims: Heart failure (HF) patients are at high-risk of cardiovascular (CV) events, including CV death. Nonetheless, a substantial proportion of these patients die from non-CV causes. Identifying patients at higher risk for each individual event may help selecting patients for clinical trials and tailoring cardiovascular therapies. The aims of the present study are to: (i) characterize patients according to CV vs. non-CV death; (ii) develop models for the prediction of the respective events; (iii) assess the models' performance to differentiate CV from non-CV death.Methods and Results: This study included 2309 patients with HF from the BIOSTAT-CHF (a systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure) study. Competing-risk models were used to assess the best combination of variables associated with each cause-specific death. Results were validated in an independent cohort of 1738 HF patients. The best model to predict CV death included low blood pressure, estimated glomerular filtration rate ≤ 60 mL/min, peripheral oedema, previous HF hospitalization, ischaemic HF, chronic obstructive pulmonary disease, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), and troponin (c-index = 0.73). The non-CV death model incorporated age > 75 years, anaemia and elevated NT-proBNP (c-index = 0.71). Both CV and non-CV death rose by quintiles of the risk scores; yet these models allowed the identification of patients in whom absolute CV death rates clearly outweigh non-CV death ones. These findings were externally replicated, but performed worse in a less severely diseased population.Conclusions: Risk models for predicting CV and non-CV death allowed the identification of patients at higher absolute risk of dying from CV causes (vs. non-CV ones). Troponin helped in predicting CV death only, whereas NT-proBNP helped in the prediction of both CV and non-CV death. These findings can be useful both for tailoring therapies and for patient selection in HF trials in order to attain CV event enrichment. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
49. Cancer and heart disease: associations and relations.
- Author
-
Boer, Rudolf A., Meijers, Wouter C., Meer, Peter, Veldhuisen, Dirk J., de Boer, Rudolf A, van der Meer, Peter, and van Veldhuisen, Dirk J
- Subjects
HEART diseases ,CANCER ,OXIDATIVE stress ,IMMUNE system ,HEART failure - Abstract
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) disease and heart failure (HF), and patients with HF frequently die from cancer. Recently, data have been generated showing that circulating factors in relation to HF promote tumour growth and development in murine models, providing proof that a causal relationship exists between both diseases. Several common pathophysiological mechanisms linking HF to cancer exist, and include inflammation, neuro-hormonal activation, oxidative stress and a dysfunctional immune system. These shared mechanisms, in combination with risk factors, in concert may explain why patients with HF are prone to develop cancer. Investigating the new insights linking HF with cancer is rapidly becoming an exciting new field of research, and we herein review the most recent data. Besides insights in mechanisms, we call for clinical awareness, that is essential to optimize treatment strategies of patients having developed cancer with a history of HF. Finally, ongoing and future trials should strive for comprehensive phenotyping of both CV and cancer end points, to allow optimal usefulness of data, and to better describe and understand common characteristics of these two lethal diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. Sudden cardiac death in heart failure: more than meets the eye.
- Author
-
Mulder, Bart A., van Veldhuisen, Dirk J., and Rienstra, Michiel
- Subjects
- *
CARDIAC arrest , *HEART failure , *ARRHYTHMIA , *LEFT ventricular dysfunction , *CARDIAC contraction , *IMPLANTABLE cardioverter-defibrillators , *DISEASE complications - Abstract
The question is therefore, why are we unable to identify HF patients at high risk for SCD and what do we know about SCD in HF? Of the total population, this implies that 6.7% of patients died due to SCD during a median follow-up of 27 months, indicating that even today, with contemporary HF therapy, including ICD therapy, SCD is still prevalent and is a serious problem. B This article refers to 'Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis' by L.E. Rohde I et al i ., published in this issue on pages 1346-1356. b Sudden cardiac death (SCD) remains an important mode of death for patients with heart failure (HF).1 Many deaths are unwitnessed, and without rhythm monitoring at the time of the event a definitive mode of death is difficult to establish. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.